Press Releases May 8, 2026 08:30 AM

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics to present at the 2026 Bank of America Healthcare Conference

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ACRS

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced it will participate in the 2026 Bank of America Healthcare Conference where its President and COO will present the company's pipeline and developments. The presentation will be webcast live and archived for investor access.

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
ACRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aclaris Therapeutics is focused on developing novel treatments for immuno-inflammatory diseases.
  • The company will present at a major healthcare conference, providing an update on its clinical-stage product candidates.
  • Aclaris maintains a robust R&D engine with a multi-stage portfolio addressing unmet medical needs in the immuno-inflammatory sector.

WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris’ President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]


Risks

  • Clinical-stage biopharmaceutical companies face regulatory and development risks which could impact future product approvals and marketability.
  • The company’s treatments are for immuno-inflammatory diseases with currently unsatisfactory treatment options, indicating potential market and reimbursement uncertainties.
  • No new data or breakthroughs were announced in this release; investor reaction may depend on content revealed during the presentation, which carries typical execution and communication risks.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026